Moody Aldrich Partners LLC bought a new position in shares of Zymeworks Inc (NYSE:ZYME) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 32,037 shares of the company’s stock, valued at approximately $1,156,000. Moody Aldrich Partners LLC owned 0.07% of Zymeworks at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the stock. Peregrine Capital Management LLC lifted its position in shares of Zymeworks by 12.8% during the 2nd quarter. Peregrine Capital Management LLC now owns 202,566 shares of the company’s stock worth $7,307,000 after buying an additional 23,057 shares during the period. Raymond James & Associates lifted its position in shares of Zymeworks by 11.1% during the 2nd quarter. Raymond James & Associates now owns 131,678 shares of the company’s stock worth $4,750,000 after buying an additional 13,134 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Zymeworks in the 2nd quarter valued at $44,000. Vident Investment Advisory LLC raised its position in Zymeworks by 15.4% in the 2nd quarter. Vident Investment Advisory LLC now owns 39,096 shares of the company’s stock valued at $1,411,000 after purchasing an additional 5,213 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. raised its position in Zymeworks by 48.3% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 344,484 shares of the company’s stock valued at $12,426,000 after purchasing an additional 112,215 shares during the last quarter. Institutional investors and hedge funds own 71.99% of the company’s stock.
Several equities analysts have issued reports on the company. Citigroup lifted their price objective on Zymeworks from $49.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. Zacks Investment Research downgraded Zymeworks from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. HC Wainwright cut their price objective on Zymeworks from $60.00 to $54.00 and set a “buy” rating for the company in a research report on Thursday, July 9th. Paradigm Capital reiterated a “buy” rating and issued a $51.00 price objective on shares of Zymeworks in a research report on Friday, May 8th. Finally, Raymond James set a $60.00 price objective on Zymeworks and gave the company a “strong-buy” rating in a research report on Thursday, July 16th. Three equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $50.92.
Zymeworks (NYSE:ZYME) last announced its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.15) by $0.51. The company had revenue of $8.27 million during the quarter, compared to analysts’ expectations of $7.78 million. Zymeworks had a negative net margin of 629.37% and a negative return on equity of 46.17%. On average, equities research analysts predict that Zymeworks Inc will post -3.37 EPS for the current fiscal year.
Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors.
Further Reading: Should You Consider an Index Fund?
Want to see what other hedge funds are holding ZYME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zymeworks Inc (NYSE:ZYME).
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.